GSK vs. RGEN: GSK vs. Repligen Stock Comparison

Company Profile

GSK (GSK) and Repligen (RGEN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but GSK is classified in Pharmaceuticals while RGEN is classified in Life Sciences Tools & Services.

Repligen (RGEN) trades as ordinary local shares, while GSK (GSK) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Repligen (RGEN) reports a negative ROE of -0.57%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile GSK (GSK) reports 28.27%, ranking against industry peers normally.

Repligen (RGEN) reports a negative net margin of -1.47%, usually indicating a net loss over the period. Meanwhile GSK (GSK) reports 12.97%, ranking against industry peers normally.

GSK (GSK) at 32.14% operates in the top operating margin quartile, ahead of Repligen (RGEN) at 6.19%, which runs around its industry’s norm.

Profitability Metrics

Growth

Both GSK (GSK) at 4.11% and Repligen (RGEN) at 16.36% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: GSK (GSK) reports EPS growth of 123.15%, ranked against its industry; Repligen (RGEN) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Repligen (RGEN) at 9.88 keeps current ratio within its industry’s typical mid-range, while GSK (GSK) at 0.86 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for GSK.

Repligen (RGEN) at 0.33 carries an industry-typical debt-to-equity mix, while GSK (GSK) at 1.30 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Repligen (RGEN) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile GSK (GSK) reports a yield of 1.57%, ranking against industry peers normally.

Repligen (RGEN) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile GSK (GSK) reports a payout of 63.33%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: GSK (GSK) trades at 17.54 times trailing earnings, ranked against its peers, while Repligen (RGEN) has no P/E ratio this period.

GSK (GSK) at 3.01 sits in the cheaper P/S ratio quartile while Repligen (RGEN) at 13.77 prices around its industry’s middle — GSK costs less per dollar of sales, though read it alongside growth and margins.

On P/B ratio, both GSK (GSK) at 4.02 and Repligen (RGEN) at 4.70 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics